EU health regulator warns some hep C drugs could reactivate
The European Medicines Agency warned on Friday that some of the most successful hepatitis C treatments on the market could reactivate hepatitis B in patients, the second time this year it has raised safety concerns over these treatments.

The latest health warning covers some of the top-selling products in the multi-billion dollar hepatitis C market, including Sovaldi, Exviera, Viekirax, Olysio and Daklinza....

http://health.economictimes.indiatimes.com/news/diagnostics/eu-health-regulator-warns-some-hep-c-drugs-could-reactivate-hep-b/55765561
Like
Comment
Share